Bridgeway Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bridgeway Capital Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-27,224	Closed	-$610K	–	1428
2019 Q1	$610K	Sell	27,224 -16,000	-37%	-$344K	0.01%	963
2018 Q4	$787K	Hold	43,224	–	–	0.01%	832
2018 Q3	$782K	Buy	43,224 +2,224	+5%	+$26.4K	0.01%	997
2018 Q2	$408K	Hold	41,000	–	–	﹤0.01%	1191
2018 Q1	$218K	Buy	+41,000	New	+$293K	﹤0.01%	1261

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bridgeway Capital Management's RARX Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2019, closing a stake of 27,224 shares — an estimated $610K sold.

Bridgeway Capital Management first reported a position in RARX in Q1 2018 and held it in 5 quarters. The position peaked at $787K in Q4 2018. 118 funds tracked by Wall St. Rank hold RARX as of Q2 2019.

Bridgeway Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 27,224 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $610K.
Bridgeway Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Bridgeway Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $787K in Q4 2018.
118 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.